[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human)
Cat. No. 1172
Biological ActivityVIP receptor antagonist; inhibits [125I]iodo-VIP binding and selectively inhibits VIP- and GRF-induced effects on adenylyl cyclase.
(Modifications: Tyr-1 = N-terminal Ac, Phe-2 = D-Phe, Arg-29 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Nowak et al (1994) Evidence that endogenous vasoactive intestinal peptide (VIP) is involved in the regulation of rat pituitary-adrenocortical function: in vivo studies with a VIP antagonist. Neuropeptides 27 297. PMID: 7862261.
Waelbroeck et al (1985) Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology 116 2643. PMID: 2859987.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human), supplier, VIP, antagonist, Vasoactive, Intestinal, Peptide, Receptors, VPAC, [Ac-Tyr1D-Phe2]GRF1-29, amide, (human), Tocris Bioscience, VIP Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
April 10 - 13, 2017